Update on perioperative bridging in patients on chronic oral anticoagulation

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 12, 2009, Pages 1533-1539

  Faltas, Bishoy ^a   Kouides, Peter A ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Bridging; Low molecular weight heparin; Oral anticoagulation; Perioperative; Surgery; Unfractionated heparin

Indexed keywords

ANTIVITAMIN K; ARGATROBAN; DABIGATRAN ETEXILATE; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; KIDNEY FAILURE; LOW DRUG DOSE; MORBID OBESITY; OSTEOPENIA; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PROSTHETIC VALVE THROMBOSIS; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL PATIENT; THROMBOEMBOLISM; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; EVIDENCE-BASED MEDICINE; HEPARIN; HUMANS; PERIOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 73349108103     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.128     Document Type: Review

References (41)

1. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 97, 1231-1233 (1998).
2. American Heart Association. 2002 Heart and Stroke Statistical Update. American Heart Association, TX, USA (2001).
3. Spyropoulos AC, Bauersachs RM, Omran H, Cohen M. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr. Med. Res. Opin. 22, 1109-1122 (2006).
4. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch. Intern. Med. 163, 901-908 (2003).
5. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J. Thromb. Haemost. 5, 2211-2218 (2007).
6. Douketis JD, Crowther MA, Cherian SS. Perioperative anticoagulation in patients with chronic atrial fibrillation who are undergoing elective surgery: results of a physician survey. Can. J. Cardiol. 16, 326-330 (2000).
7. Douketis JD, Crowther MA, Cherian SS, Kearon CB. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 116, 1240-1246 (1999).
8. Douketis JD, Berger PB, Dunn AS et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, S299-S339 (2008).
9. Spyropoulos AC. Bridging of oral anticoagulation therapy for invasive procedures Curr. Hematol. Rep. 4, 405-413 (2005).
10. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb. Res. 108, 3-13 (2002).
11. Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr. Opin. Pulm. Med. 11, 373-379 (2005).
12. Lindberg F, Bergqvist D, Rasmussen I. Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. Surg. Laparosc. Endosc. 7, 324-331 (1997).
13. Nutescu EA, Shorr AF, Farrelly E, Horblyuk R, Happe LE, Franklin M. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery. Ann. Pharmacother. 42, 1216-1221 (2008).
14. Kearon C. Management of anticoagulation in patients who require invasive procedures. Semin. Vasc. Med. 3, 285-294 (2003).
15. Longstreth WT Jr, Bernick C, Fitzpatrick A et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 56, 368-375 (2001).
16. Durrleman N, Pellerin M, Bouchard D et al. Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute. J. Thorac. Cardiovasc. Surg. 127, 1388-1392 (2004).
17. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am. Heart J. 156, 57-64 (2008).
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
19. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler. Thromb. Vasc. Biol. 29, 298-310 (2009).
20. Dunn AS, Wisnivesky J, Ho W, Moore C, McGinn T, Sacks HS. Perioperative management of patients on oral anticoagulants: a decision analysis. Med. Decis. Making 25, 387-397 (2005).
21. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann. Intern. Med. 122, 40-42 (1995).
22. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin. Pharmacokinet. 30, 300-313 (1996).
23. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am. Heart J. 96, 163-165 (1978).
24. Spyropoulos AC, Turpie AG, Dunn AS et al. Clinical outcomes with unfractionated heparin or low-molecularweight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J. Thromb. Haemost. 4, 1246-1252 (2006).
25. Amorosi SL, Tsilimingras K, Thompson D, Fanikos J, Weinstein MC, Goldhaber SZ. Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am. J. Cardiol. 93, 509-511 (2004).
26. Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am. J. Cardiol. 93, 247-250 (2004).
27. Douketis JD, Johnson JA, Turpie AG. Lowmolecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med. 164, 1319-1326 (2004).
28. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, S340-S380 (2008).
29. Hammerstingl C, Omran H, Bonn Registry of Alternative Anticoagulation to Prevent Vascular Events. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. Thromb. Haemost. 101, 1085-1090 (2009).
30. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, S188-S203 (2004).
31. Goldhaber SZ. "Bridging" and mechanical heart valves: perils, promises, and predictions. Circulation 113, 470-472 (2006).
32. Seshadri N, Goldhaber SZ, Elkayam U et al. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am. Heart J. 150, 27-34 (2005).
33. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch. Intern. Med. 160, 2033-2041 (2000).
34. Karmy-Jones R, Jurkovich GJ, Velmahos GC et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J. Trauma 62, 17-24; discussion 24-25 (2007).
35. Ingber S, Geerts WH. Vena caval filters: current knowledge, uncertainties and practical approaches. Curr. Opin. Hematol. 16(5), 402-406 (2009).
36. Kaufman JA, Rundback JH, Kee ST et al. Development of a research agenda for inferior vena cava filters: proceedings from a multidisciplinary research consensus panel. J. Vasc. Interv. Radiol. 20, 697-707 (2009).
37. Goldstein JL, Larson LR, Yamashita BD, Fain JM, Schumock GT. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study. Am. J. Gastroenterol. 96, 2360-2366 (2001).
38. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 125, 1642-1650 (2004).
39. Turpie AG. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update. Curr. Opin. Drug Discov. Devel. 12, 497-508 (2009).
40. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and Factor Xa inhibitors in development. Clin. Pharmacokinet. 48, 1-22 (2009).
41. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).